We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Mirati

News List

Mirati Announces Executive Management Changes americanpharmaceuticalreview
January 09, 2020
Mirati Therapeutics has announced changes to their executive management team, effective immediately. Mirati continues to accelerate the development of the KRAS and sitravatinib programs ...
Mirati Announces Clinical Collaboration with Novartis americanpharmaceuticalreview
July 11, 2019
Mirati Therapeutics announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumor
Mirati Announces Collaboration with Bristol-Myers Squibb for Sitravatinib, OPDIVO Trial americanpharmaceuticalreview
January 09, 2019
Mirati Therapeutics announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO)....
Mirati Announces Clearance of IND Application for MRTX849 Trial americanpharmaceuticalreview
December 03, 2018
Mirati Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for .....